Description
Contact hours available until 12/31/2017.
Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.
Nephrology Nursing Journal Editorial Board Statements of Disclosure:
In accordance with ANCC governing rules Nephrology Nursing Journal Editorial Board statements of disclosure are published with each CNE offering.
Paula Dutka MSN, RN, CNN, disclosed that she is a coordinator of Clinical Trials for the following sponsors: Amgen, Rockwell Medical, Keryx Biopharmaceuticals, Akebia Therapeutics, and Dynavax Technologies.
Norma J. Gomez, MBA, MSN, CNNe, disclosed that she is a member of the ZS Pharma Advisory Council.
Carol M. Headley DNSc, ACNP-BC, RN, CNN, disclosed that she is a Consultant and/or member of the Corporate Speaker’s Bureau for Sanofi Renal, and a member of the Advisory Board for Amgen.
Tamara M. Kear, PhD, RN, CNS, CNN, disclosed that she is a Fresenius employee, and freelance editor for Lippincott, Williams & Wilkins and Elsevier publishing companies.
All other members of the Editorial Board had no actual or potential conflict of interest in relation to this continuing nursing education activity.
This article was reviewed and formatted for contact hour credit by Beth Ulrich, EdD, RN, FACHE, FAAN, Nephrology Nursing Journal Editor, and Sally Russell, MN, CMSRN, CPP ANNA Education Director.
There are no other disclosures to declare.
This article was reviewed and formatted for contact hour credit by Beth Ulrich, EdD, RN, FACHE, FAAN, Nephrology Nursing Journal Editor, and Sally Russell, MN, CMSRN, CPP ANNA Education Director.
Commercial Support and Sponsorship:
No commercial support or sponsorship declared.
Accreditation Statement:
American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Goal
List several possible differential diagnoses for a patient doing peritoneal dialysis that develops “black”-appearing dialysate effluent.
Objectives:
- Discuss the indications for colonoscopy in the end stage renal disease (ESRD) population compared to the general population.
- List specific areas of assessment that need to be included in the evaluation of a patient doing peritoneal dialysis who develops a change in the character of their peritoneal dialysate effluent.
- Explain the rationale for including an individual’s recent exposures in determining the cause for a change in the appearance of their peritoneal dialysate effluent.
